Unlock instant, AI-driven research and patent intelligence for your innovation.

Phosphorylated cop1 molecules and uses thereof

A phosphorylation and molecular technology, applied in compound screening, analytical materials, biological material analysis, etc., can solve problems such as reducing p53

Inactive Publication Date: 2009-03-11
GENENTECH INC
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Furthermore, ATM phosphorylates MDM2 and MDMX, reducing their ability to negatively regulate p53 14-16

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Phosphorylated cop1 molecules and uses thereof
  • Phosphorylated cop1 molecules and uses thereof
  • Phosphorylated cop1 molecules and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0166] Methods for preparing formulations known in the art can be found, for example, in "Remington's Pharmaceutical Sciences" (19th Edition), Ed. A. Gennaro, 1995, Mack Publishing Company, Easton, Pa. Formulations for parenteral administration may, for example, contain excipients, sterile water or saline, poly(alkylene) glycols such as polyethylene glycol, vegetable oils or hydrogenated naphthalenes. Biocompatible, biodegradable lactide polymers, lactide / glycolide copolymers, or polyoxyethylene-polyoxypropylene copolymers can be used to control the release of the compounds. Other potentially useful parenteral delivery systems include ethylene-vinyl acetate copolymer particles, osmotic pumps, implantable infusion systems, and liposomes. Formulations for inhalation may contain excipients such as lactose, or may be aqueous solutions containing, for example, polyoxyethylene-9-lauryl ether, glycocholate and deoxycholate, or may be in the form of nasal drops or Oily solution ...

Embodiment 1

[0172] Example 1: Materials and methods

[0173] Expression Vectors, Recombinant Proteins and Antibodies

[0174] FLAG-COP1, pcDNA3.1+p53, p21-Luc, bax-Luc, pGEX4T1-p53 and pGEX6P1-COP1 have been described previously 3,21 . The GST-S387 peptide contains amino acids 377-400 of the human COP1 polypeptide, while the GST-S387-A peptide has an alanine mutation at S387. FLAG-ATM and FLAG-ATM-KD were donated by Professor Michael Kastan (St. Jude Children’s Research Hospital, TN). All mutant constructs were generated by Quickchange site-directed mutagenesis (Stratagene). All GST recombinant proteins were expressed in E. coli BL21(DE3) codon+ (Stratagene) followed by purification using Glutathione Sepharose 4B batch method (GE Healthcare). Anti-p53(DO-1)(Calbiochem), Anti-p53 pS15(Cell Signaling), Anti-p21(Ab-1)(Calbiochem), Anti-FLAG(M2)(Sigma), Anti-Myc(9E10)(Roche), Anti-Muscle Actin (ICN), anti-tubulin (Ab6161) (Abcam), anti-histone H1 (SC8030) (Santa Cruz Biotechnology), an...

Embodiment 2

[0183] Example 2: COP1 is post-translationally modified upon exposure to IR

[0184] The present inventors examined COP1 steady state levels after induction of DNA damage with 10 Gy IR using GM0637 fibroblasts. Lysates probed with antibodies to COP1 revealed that steady-state levels of COP1 began to decline as early as 30 minutes after IR and nearly disappeared by 1 hour (Fig. 1A). Notably, as COP1 levels decreased, steady-state levels of p53 increased, consistent with activation of the downstream target gene p21 (Fig. 1A and 1B). To reveal the mechanism of this COP1 protein reduction, real-time PCR was performed to evaluate gene activity at the COP1 locus. COP1 mRNA levels were moderately elevated following IR stimulation. Two classical p53-dependent promoters, the p21 and PUMA promoters, were also induced after IR stimulation, although their magnitude was much larger than that of the COP1 promoter. Therefore, these data imply that decreased COP1 protein levels cannot be a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
Login to View More

Abstract

The invention provides COP1 molecules and modulators of COP1 activity and methods of using them, including diagnostic and therapeutic uses thereof. Such molecules can be useful for detecting DNA damage and modulating the response to DNA damage and p53 activity in subjects. The invention also provides reagents and kits for use in screening for test compounds that can modulate COP1 activity.

Description

[0001] related application [0002] This application claims priority to and benefit of US Provisional Application Serial No. 60 / 755,412 filed December 31, 2005, the specification of which is hereby incorporated in its entirety. field of invention [0003] The present invention belongs to the field of diagnosis and treatment of COP1 and DNA damage. Background of the invention [0004] In mammals, genome integrity is a prerequisite for maintaining cellular and tissue homeostasis. Thus, a specialized group of proteins has been drawn into a coalition designed to resist potential genome perturbations. Ataxia telangiectasia (A-T) is a rare autosomal recessive disorder in which individuals harbor severe genomic instability at the cellular level 1 . Mutations in ataxia telangiectasia mutant protein kinase (ATM) are associated with A-T, implicating ATM as an essential component of a DNA damage response network constructed to maintain genome integrity 2 . ATM functions in part by...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/25G01N33/50
CPCG01N2500/02G01N2333/9015C12Q1/25G01N33/57496A61P35/00A61P43/00G01N33/5023
Inventor 戴维·多南
Owner GENENTECH INC